Evaluation of autoantibody positive in multiple sclerosis patients

Şeyda Figül Gökçe; Burhanettin Çiğdem

doi:https://doi.org/10.7197/223.vi.480337

Makale detayları

Evaluation of autoantibody positive in multiple sclerosis patients

Yazarlar:

Şeyda Figül Gökçe | Burhanettin Çiğdem

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Cumhuriyet Medical Journal 2019 Vol.41 Issue 1, pp.104-109

Belge Tipi:

Makale

Yayın Tarihi:

3/2019

Belge Dili:

İngilizce

Document ID (Org No.):

2000922614

DOI:

https://doi.org/10.7197/223.vi.480337

Anahtar kelimeler:

Özet:

 


Objective: Multiple sclerosis (MS) is the most
common autoimmune disease of the central nervous system in which impaired
immune activation is involved. It is known that other autoimmune diseases are
seen more frequently in MS patients.  Many
rheumatologic diseases could cause neurologic disorders that mimic MS.  Our aim in this
study is to determine the rates of autoantibody positivity and the clinical significance of these positivity rates in patients with MS.


Method: 110 patients who were followed up with MS diagnosis in our clinic between
2008 and 2018  were retrospectively
evaluated for autoimmune disease biomarkers. The
diagnosis of MS was confirmed using both 2005 and 2010 Revised Mc Donald
Criteria. 


Results: The ANA (antinuclear antibody)
positivity rate in our patients was 10.9%, 
the ANA profile positivity was 9.1%. Anti-ds DNA (double stranded
deoxyribonucleic acid) positivity rate was 1.8%, anti-cardiolipin Ig
(immunglobulin) G and Ig M were 0.9% positive. Anti-microsomal antibody
positivity was 11.8% while anti-thyroglobulin antibody was positively 13.6%.
The value of complement 3 (C3) was found to be 92.7% normal and 4.5% higher and
2.7% lower, respectively. The C4 values were 98.2% normal, while they were
11.8% higher than normal .


Six patients had six different
diseases  in which ethiopathogenesis the role of autoimmunity was also revealed ( ankylosing spondylitis, psoriasis,
systemic lupus erythematosus, morfea, ptriyazis, Sjögren's syndrome).  











Conclusions: Although some autoantibody positivities
in MS patients are more frequent than healthy controls, these positivities are
not usually associated with systemic rheumatologic disease and haven’t clinical
significance. Therefore, the evaluation of autoantibodies in each MS patient
does not seem cost effective. So, the MS patients whose autoantibody levels are
to be measured should be well selected before the evaluation the patients'
medical history and complaints should be taken into consideration.



.

 






Sonuç: MS hastalarında
otoantikor pozitifliklerinin bazıları topluma göre daha sık olsa da çoğunlukla
bu otoantikor pozitiflikleri sistemik romatolojik hastalık varlığı ile ilişkili
değildir ve klinik açıdan anlam içermemektedir. Bu nedenle her MS hastasında
otoantikorların araştırılması maliyet açısından etkin görünmemektedir. Bu
yüzden otoantikor düzeyi ölçülecek MS hastaları iyi seçilmeli ve ölçüm öncesinde
hastaların öykü ve yakınmaları dikkate alınmalıdır. 


.

Makale detayları

Evaluation of autoantibody positive in multiple sclerosis patients

Yazarlar: Şeyda Figül Gökçe | Burhanettin Çiğdem

Ana Başlıklar: Sağlık teşvikleri

Dergi: Cumhuriyet Medical Journal 2019 Vol.41 Issue 1, pp.104-109

Belge Tipi: Makale

Yayın Tarihi: 3/2019

Belge Dili: İngilizce

Document ID (Org No.): 2000922614

DOI: https://doi.org/10.7197/223.vi.480337

Multiple sclerosis

autoimmune disease

rheumatologic disease

autoantibody

Sayı

Yazarlar:

Şeyda Figül Gökçe | Burhanettin Çiğdem

Ana Başlıklar:

Sağlık teşvikleri

Dergi:

Cumhuriyet Medical Journal 2019 Vol.41 Issue 1, pp.104-109

Belge Tipi:

Makale

Yayın Tarihi:

3/2019

Belge Dili:

İngilizce

Document ID (Org No.):

2000922614

DOI:

https://doi.org/10.7197/223.vi.480337